

4

Docket No. G-046US02PCT  
Serial No. 09/762,311REMARKS


Claims 1-39 were initially pending in the parent application. By way of a Preliminary Amendment, filed simultaneously with this 371 application, claims 2-4, 9, 10, 14, 15, 17-21, 28-32, 34, and 36-38 were cancelled without prejudice, claims 1, 6, 7, 8, 11, 12, 13, 16, 22, 25-27, 33, 35, 39, were amended, and claims 40-43 were added. On or about September 2, 2002, a second Preliminary Amendment was submitted to the Patent Office, canceling claims 1-41 and adding claims 42-63. By way of the amendment of this date, certain of the claims have been amended to resolve antecedent basis issues.

Accordingly, claims 42-63 are pending in this application. By way of the response of this date, Applicants hereby elect, with traverse, Group I (claims 42-57 and 59) drawn to a composition comprising nucleotide sequences of TBC-1 and a method of making the polypeptide; further, Applicants also elect the biallelic marker in position 9494 of SEQ ID NO:1. Favorable consideration of the claims in view of this response, and in view of the remarks set forth herein, is earnestly solicited.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants also invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Telephone No.: (352) 375-8100

Facsimile No.: (352) 372-5800

Address : Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2431 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/jaj

Attachment: Marked-Up Version of Amended Claims

J:\GEN\046.US02.PCT\Amend-Resp\Election-Amendment.doc\DNB\jaj

1

Docket No. G-046US02PCT  
Serial No. 09/762,311MARKED-UP VERSION OF AMENDED CLAIMSClaim 43. (Amended):

A composition comprising an isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of at least 12 nucleotides of any one of SEQ ID NOs:1 and 2 or the complement thereof, wherein said span includes a *TBC-1*-related biallelic marker in said sequence.

Claim 44. (Amended):

The ~~polynucleotide composition~~ according to claim 43, wherein said *TBC-1*-related biallelic marker is selected from the group consisting of the biallelic markers in positions 9494 of SEQ ID NO:1, and 1443, 5247, 6223, 14723, 19186, 18997, 19891, 29617, 42519, 69324, 69181, 69146, 76458, 78595, 82159, 84522, 84810, and 89967 of SEQ ID NO:2.

Claim 45. (Amended):

The ~~polynucleotide composition~~ according to claim 43, wherein said contiguous span is at least 18 ~~to or at least~~ 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide.

Claim 46. (Amended):

The ~~polynucleotide composition~~ according to claim ~~45~~43, wherein said polynucleotide consists of said contiguous span and said contiguous span is at least 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide.

Claim 47. (Amended):

The ~~polynucleotide composition~~ according to claim 43, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

Claim 51. (Amended):

The ~~composition according to claim 43, wherein the polynucleotide according to claim 43 is~~ attached to a solid support.

2

Docket No. G-046US02PCT  
Serial No. 09/762,311Claim 52. (Amended):

An array of polynucleotides comprising at least one polynucleotide according to claim 51. A composition according to claim 43, wherein the composition comprises an array of polynucleotides attached to a solid support and at least one polynucleotide consists essentially of a contiguous span of at least 12 nucleotides of any of SEQ ID NO:1 and 2 or the complement thereof and the span includes a TBC-1-related biallelic marker.

Claim 54. (Amended):

The composition according to claim 43, wherein the polynucleotide according to claim 43 further comprising comprises a label.